http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014140432-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-726 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-50 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57488 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2013-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014140432-A |
| titleOfInvention | METHOD FOR FORECASTING RISK OF DEVELOPMENT OF MALIGNANT NOVOGRAPHY OR DIAGNOSIS OF MALIGNANT NOVOLEMENTATION IN A SPECIAL FEMALE |
| abstract | 1. A method for predicting the risk of developing a malignant neoplasm in a female individual that does not suffer from a malignant neoplasm, comprising: - determining the level of pro-neurotensin 1-117 or fragments thereof from at least 5 amino acids or pro-neurotensin 1-117 containing peptides , in biological fluid obtained from the indicated female; and - correlation of the indicated level of pro-neurotensin 1-117 or its fragments or pro-neurotensin 1-117 containing peptides with a risk of developing malignant neoplasm, where an increased level is prognostic for an increased risk of developing malignant neoplasm and, where said malignant neoplasm is selected from breast cancer, lung cancer, pancreatic cancer, and colon cancer. 2. The method of claim 1, wherein said malignant neoplasm is breast cancer. The method of claim 1 or 2, wherein the elevated level denotes a level above a threshold level. A method according to claim 1 or 2, wherein the level of pro-neurotensin 1-117 or fragments thereof of at least 5 amino acids or pro-neurotensin 1-117 containing peptides in the biological fluid is an empty stomach. The method of claim 1 or 2, wherein in said female, a malignant neoplasm has never been previously diagnosed during sampling of a biological fluid from said female. The method according to claim 1 or 2, wherein a malignant neoplasm was diagnosed in the indicated female and was cured during the sampling of the biological fluid from the indicated female, and the risk of relapse is determined |
| priorityDate | 2012-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419581080 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID25078013 |
Total number of triples: 19.